rimegepant Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Rimegepant, sold under the brand name Nurtec ODT among others, is a medication used for the acute treatment of migraine with or without aura in adults and the preventative treatment of episodic migraine in adults. It is taken by mouth to dissolve on or under the tongue. It works by blocking CGRP receptors.   Wikipedia

Chemistry

  • SMILES: N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)N3C(=O)Nc4ncccc34)c5ncccc15)c6cccc(F)c6F
  • InChIKey: KRNAOFGYEFKHPB-ANJVHQHFSA-N
  • Mol. Mass: 534.57
  • ALogP: 4.49
  • ChEMBL Molecule:
    rimegepant  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$79.3863 - $106.9964
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta(b)pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxylate | bms-927711 | rimegepant

Organizations (9)

Research & Development (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Migraine Disorders (Phase 4)

Pain (Phase 4)

Psoriasis (Phase 2)

Trigeminal Neuralgia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial Organizations: 9

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue